Abstract
Clofibrate (Atromid S - ICI) is the drug most widely used in this country for reducing abnormally high plasma lipids, and for treating xanthomatosis.1 It is not effective in all forms of hyperlipidaemia, but until now it has not been known to raise lipid levels. A recent report, however, describes four patients with primary biliary cirrhosis and hypercholesterolaemia in whom clofibrate raised the serum cholesterol. In three of the patients the skin xanthomas became more severe. When clofibrate was discontinued the cholesterol level fell again. The explanation for this surprising effect so far remains obscure. Clofibrate did not affect bilirubin, alkaline phosphatase and transaminase levels.2 We conclude that the drug should not be used in patients with biliary cirrhosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
